Riluzole PMCS ( DrugBank: Riluzole )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 18 | Spinocerebellar degeneration | 1 |
18. Spinocerebellar degeneration
Clinical trials : 71 / Drugs : 99 - (DrugBank : 30) / Drug target genes : 45 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-001481-23-FR (EUCTR) | 12/09/2017 | 30/10/2017 | NA | MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL WITH RILUZOLE IN SPINOCEREBELLAR ATAXIA TYPE 2 - ATRIL | SCA2 patients, both gender, at least 18 years of age MedDRA version: 20.0;Level: PT;Classification code 10057660;Term: Spinocerebellar ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Riluzole PMCS Product Name: Riluzole PMCS INN or Proposed INN: Riluzole Other descriptive name: Riluzole | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France |